<DOC>
	<DOCNO>NCT03065387</DOCNO>
	<brief_summary>There 2 part clinical research study : Part 1 ( dose escalation ) Part 2 ( expansion ) . The goal Part 1 study find high tolerable dose neratinib combination everolimus , Ibrance ( palbociclib ) , trametinib give patient advance cancer specific mutation ( EGFR , HER2 , HER3 , HER4 ) . The goal Part 2 study learn dose neratinib combination everolimus , Ibrance ( palbociclib ) , trametinib find Part 1 help control advance cancer patient specific mutation . The safety drug also study part study .</brief_summary>
	<brief_title>Study Pan-ERBB Inhibitor Neratinib Given Combination With Everolimus , Palbociclib Trametinib Advanced Cancer Subjects With EGFR Mutation/Amplification , HER2 Mutation/Amplification HER3/4 Mutation</brief_title>
	<detailed_description>Study Groups : Depending type disease participant join study , participant receive 1 3 drug combination : - Group A : Neratinib Everolimus - Group B : Neratinib Palbociclib - Group C : Neratinib Trametinib Up 40 participant enrol study group . If participant find eligible take part study , participant assign study drug dose base participant join study . About 3-6 participant enrol per study drug dose . If participant Part 2 , participant receive neratinib combination everolimus , palbociclib , trametinib high dose safe tolerate Part 1 . A total 18-90 participant enrol Part 1 study . About 10 participant enrol per group total 30 participant enrol Part 2 . If participant Part 1 , dose neratinib combination everolimus , palbociclib , trametinib receive depend participant join study . The study doctor let know study group part study participant participate . Study Drug Administration : Each study cycle 28 day . The following direction participant Part 1 Part 2 . Participant take neratinib mouth 1 time day food , preferably morning , every day . If participant miss dose ( ) neratinib , make miss dose ( ) . However , less 6 hour since participant meant take participant 's dose , participant may take participant 's dose day soon participant remembers . It important participant take neratinib time every day . Neratinib must store room temperature direct sunlight . There 30 minute wait period participant 's dose neratinib participant 's study drug ( ) Cycle 1 . After , wait period . If participant Group A , participant take everolimus mouth 1 time day neratinib every day . Everolimus must store room temperature , keep dry away light . If participant Group B , participant take palbociclib mouth 1 time day neratinib , every day 3 week follow 1-week `` rest period '' cycle . Palbociclib must store room temperature . If participant Group C , participant take trametinib mouth 1 time day neratinib every day . Trametinib must store refrigerator ( freeze ) , keep dry away light . Participant also take Imodiumâ„¢ ( loperamide ) low risk diarrhea cause neratinib . Along participant 's first dose neratinib , participant take 2 tablet loperamide mouth 3 time day first 14 day Cycle 1 . After , participant take 2 tablet 2 time day rest Cycle 1 . After Cycle 1 , participant take loperamide need . If diarrhea continue despite take loperamide , participant call participant 's doctor nurse . If participant constipate , participant call participant 's study doctor discontinue Imodium use unless specifically instruct participant 's doctor . Participant 's study doctor staff contact participant first 3 day participant start take neratinib ask participant diarrhea make change participant 's treatment . Participant 's study doctor give participant separate instruction sheet explain manage diarrhea . Participant receive study drug diary participant record date time dose study drug . Participant 's study doctor also tell participant record number stool participant per day dose loperamide participant take day first cycle therapy . Participant need record dose study drug entire study . Participant need bring diary participant 's study visit . Participant must also bring unused study drug pill bottle ( even empty ) clinic Day 1 cycle . Length Treatment : Participant may continue take study drug long doctor think participant 's best interest . Participant longer able take study drug disease get bad , intolerable side effect occur , participant unable follow study direction . Study Visits : On Day 1 Cycle 1 ( test perform participant last 72 hour ) : - Participant physical exam . - Blood ( 4-5 teaspoon ) urine collect routine test . - Blood ( 4 teaspoon ) draw biomarker testing , include genetic biomarkers . - Participant EKG check participant 's heart function . - If participant become pregnant , blood ( 1 teaspoon ) drawn pregnancy test . On Days 2-4 Cycle 1 , study staff call participant ask symptom participant may . The call last 5 minute . On Days 8 , 15 , 22 Cycle 1 : - Participant physical exam . - Blood ( 4-5 teaspoon ) draw routine test . - Blood ( 4 teaspoon ) draw biomarker testing , include genetic biomarkers . - On Day 15 , blood ( 1 teaspoon time ) drawn 5 time next 5 hour study drug dose pharmacokinetic ( PK ) test . PK test measure amount study drug blood different time point . - If participant Part 2 , Day 15 , participant core excisional biopsy biomarker test ( include genetic biomarkers ) . On Day 16 Cycle 1 ( 20-28 hour participant 's Day 15 dose study drug ) , blood ( 1 teaspoon ) drawn PK testing . On Day 1 Cycles 2 beyond : - Participant physical exam . - Blood ( 4-5 teaspoon ) urine draw routine test . - Blood ( 4 teaspoon ) draw biomarker testing , include genetic biomarkers . On Day 1 Cycles 3 5 , blood ( 1 teaspoon ) drawn study drug dose PK testing . Every 8 week , participant CT scan MRI check status disease . After 6 month , participant CT scan MRI scan every 12 week . Every 12 week , participant ECHO MUGA scan . Participant may eye exam ( Group C ) routine test perform study doctor think need . End-of-Treatment Visit : After participant 's last study drug dose : - Participant physical exam . - Blood ( 6 teaspoon ) urine collect routine test check well participant 's blood clot . - Blood ( 4 teaspoon ) draw biomarker testing . - Participant may ECHO MUGA scan . This scan perform participant do last 12 week . - Participant CT scan MRI check status disease . If participant go study disease get bad , participant call every 3 month 1 year . Participant ask participant participant receive new treatment cancer . The call last 15 minute . Follow-up Visits : About 30 day participant 's last dose study drug , blood ( 4-5 teaspoon ) urine collect routine test . This investigational study . Neratinib FDA approve commercially available . It currently use research purpose . Everolimus commercially available FDA approve treatment several disease type , include breast cancer renal cell carcinoma . Palbociclib commercially available FDA approve treatment ER-positive , HER2-negative breast cancer . Trametinib commercially available FDA approve treatment melanoma BRAF V600E V600K mutation . The study doctor explain study drug design work . Up 120 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Lip Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Subjects advance metastatic solid tumor refractory standard therapy relapse standard therapy . Subjects hematologic malignancy include lymphoma/myeloma enrol study . 2 . Subjects must one following : a. somatic mutation human epidermal growth factor receptor ( EGFR , HER2 , HER3 , HER4 ) ; b. EGFR gene amplification ; c. HER2 gene amplification 3 . Subjects must measurable disease RECIST v1.1 . 4 . Subjects must &gt; /=18 year age . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 . 6 . Abnormal organ function permit . However , subject must : a. absolute neutrophil count &gt; /= 1500/mL ; b. platelet &gt; /= 100,000/mL ; c. hemoglobin &gt; /= 9 g/dL ; d. creatinine &lt; /= 1.5 X upper limit normal ( ULN ) ; e. total bilirubin &lt; /= 1.5 X ULN ; f. aspartate aminotransferase ( AST/SGOT ) and/or alanine aminotransferase ( ALT/SGPT ) &lt; /= 2.5 X ULN ( &lt; /=5 X ULN subject bone liver metastasis ) 7 . Subjects must &gt; /=4 week beyond treatment chemotherapy investigational therapy include hormonal , biological , targeted agent ; least 5 halflives hormonal , biological , targeted agent , whichever short time treatment initiation . 8 . Women childbearing potential MUST negative serum urine human chorionic gonadotropin ( HCG ) test unless prior hysterectomy menopause ( defined 12 consecutive month amenorrhea ) . Subjects become pregnant breastfeed study . Sexually active subject must agree use contraception duration study participation 4 month last dose neratinib everolimus , palbociclib trametinib . 9 . Ability understand willingness sign inform consent form prior initiation study study procedure . 10 . Only subject enrolled Arm 1 Neratinib Everolimus : Fasting lipid profile : Cholesterol le equal 350 mg/dL triglyceride less equal 400 mg/dL . 11 . Only subject enrolled Arm 1 Neratinib Everolimus : Patients take medication moderate potent inhibitor inducer CYP450 3A4 5 halflives prior start everolimus . 12 . Only subject enrolled Arm 1 Neratinib Everolimus : Monitor serum glucose level subject preexist diabetes hyperglycemia 13 . Only subject enrolled Arm 2 Neratinib Palbociclib : Any prior neuropathy back baseline grade 1 14 . Only subject enrolled Arm 2 Neratinib Palbociclib : Patients take medication moderate potent inhibitor inducer CYP450 3A4 5 halflives prior start Palbociclib . 15 . Only subject enrolled Arm 3 Neratinib Trametinib : All skin rash ( dermatitis acneiform , erythema , xeroderma , eczema ) grade 1 start trametinib treatment . 16 . Only subject enrolled Arm 3 Neratinib Trametinib : History retinal disorder , dry eye syndrome , blurry vision need evaluate ophthalmology prior start treatment . 17 . Only subject enrolled Arm 3 Neratinib Trametinib : Monitor serum glucose level subject preexist diabetes hyperglycemia 1 . Subjects pregnant breastfeeding ; 2 . Known Hepatitis B , Hepatitis C human immunodeficiency virus ( HIV ) infection . 3 . Inability unwillingness swallow pill . 4 . Active infection require intravenous ( IV ) antibiotic uncontrolled intercurrent illness require hospitalization . 5 . Clinically significant gastrointestinal ( GI ) abnormality may alter absorption malabsorption syndrome major resection stomach bowel . For example , subject 50 % large intestine remove sign malabsorption ( e.g . gastrectomy , ileal bypass , chronic diarrhea , Crohn 's disease , malabsorption , gastroparesis ) . 6 . Inability comply study followup procedure . 7 . History cerebrovascular accident ( CVA ) , myocardial infarction unstable angina within previous 6 month start therapy . 8 . Prolongation QT/QTc interval ( QTc interval &gt; 450 m male &gt; 470 ms female ) use Fridericia method QTc analysis . 9 . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . This exception include carcinomatous meningitis exclude regardless clinical stability . 10 . Uncontrolled concurrent disease illness include limited : symptomatic congestive heart failure ( NYHA Class III IV ) per NYHA Classification ( see Appendix B ) , unstable angina pectoris , clinically significant cardiac arrhythmia ; unstable untreated cardiac condition ejection fraction &lt; 50 % determine echocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) ; diabetes mellitus ( i.e . fast blood glucose &gt; 220 despite acceptable chronic diabetes therapy ) ; psychiatric illness would limit compliance study requirement , determine investigator 11 . Participating clinical trial use investigational product . 12 . Only subject enrolled Arm 1 Neratinib Everolimus : History hypersensitivity everolimus 13 . Only subject enrolled Arm 1 Neratinib Everolimus : Subjects require therapy immunosuppressive agent antitumor necrosis factor alpha ( TNFa ) agent ( Etanercept , Adalimumab ) , azathioprine , methotrexate , cyclosporine , etc active autoimmune disorder . 14 . Only subject enrolled Arm 1 Neratinib Everolimus : Major surgery &lt; /=28 day prior treatment everolimus . 15 . Only subject enrolled Arm 3 Neratinib Trametinib : Albumin le 3 Gm/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic solid tumor</keyword>
	<keyword>Genetic mutation</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Neratinib</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>Zortress</keyword>
	<keyword>RAD001</keyword>
	<keyword>Palbociclib</keyword>
	<keyword>PD-0332991</keyword>
	<keyword>Ibrance</keyword>
	<keyword>Trametinib</keyword>
</DOC>